Personalis, Inc. (PSNL)
Largest Insider Buys in Sector
PSNL Stock Price History Chart
PSNL Stock Performance
About Personalis, Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT …
Insider Activity of Personalis, Inc.
Over the last 12 months, insiders at Personalis, Inc. have bought $17.76M and sold $200,444 worth of Personalis, Inc. stock.
On average, over the past 5 years, insiders at Personalis, Inc. have bought $26.82M and sold $19.63M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Tempus AI, Inc. (10 percent owner) — $17.75M. MYERS WOODROW A JR (director) — $16,700.
The last purchase of 3,500,000 shares for transaction amount of $17.75M was made by Tempus AI, Inc. (10 percent owner) on 2024‑08‑16.
List of Insider Buy and Sell Transactions, Personalis, Inc.
| 2024-11-01 | Sale | PRESIDENT AND CEO | 26,443 0.0527% | $5.38 | $142,263 | -1.77% | ||
| 2024-08-16 | 10 percent owner | 3.5M 7.8698% | $5.07 | $17.75M | 0.00% | |||
| 2024-07-30 | Sale | CFO AND COO | 742 0.0014% | $2.97 | $2,204 | +20.20% | ||
| 2024-07-30 | Sale | CHIEF MEDICAL OFFICER AND EVP | 524 0.001% | $2.97 | $1,556 | +20.20% | ||
| 2024-06-17 | Sale | CFO AND COO | 7,176 0.0134% | $1.29 | $9,257 | +289.53% | ||
| 2024-06-17 | Sale | CHIEF MEDICAL OFFICER AND EVP | 5,055 0.0094% | $1.29 | $6,521 | +289.53% | ||
| 2024-06-17 | Sale | SVP and Chief Legal Officer | 1,585 0.003% | $1.29 | $2,045 | +289.53% | ||
| 2024-05-17 | Sale | CFO AND COO | 1,333 0.0026% | $1.38 | $1,840 | +233.93% | ||
| 2024-05-17 | Sale | CHIEF MEDICAL OFFICER AND EVP | 940 0.0018% | $1.38 | $1,297 | +233.93% | ||
| 2024-05-17 | Sale | SVP and Chief Legal Officer | 1,731 0.0033% | $1.38 | $2,389 | +233.93% | ||
| 2024-04-30 | Sale | SVP and Chief Legal Officer | 4,523 0.0083% | $1.37 | $6,197 | +134.69% | ||
| 2024-03-01 | director | 10,000 0.0206% | $1.67 | $16,700 | -2.96% | |||
| 2024-01-29 | Sale | CFO AND COO | 716 0.0013% | $1.37 | $981 | +1.64% | ||
| 2024-01-29 | Sale | CHIEF MEDICAL OFFICER AND EVP | 526 0.001% | $1.37 | $721 | +1.64% | ||
| 2023-12-15 | Sale | CFO and COO | 6,747 0.0135% | $1.47 | $9,918 | +4.64% | ||
| 2023-12-15 | Sale | Chief Medical Officer and EVP | 4,708 0.0094% | $1.47 | $6,921 | +4.64% | ||
| 2023-12-15 | Sale | General Counsel | 1,476 0.003% | $1.47 | $2,170 | +4.64% | ||
| 2023-11-16 | Sale | CFO and COO | 1,344 0.0027% | $1.04 | $1,398 | +46.92% | ||
| 2023-11-16 | Sale | Chief Medical Officer and EVP | 940 0.0019% | $1.04 | $978 | +46.92% | ||
| 2023-11-16 | Sale | General Counsel | 1,722 0.0035% | $1.04 | $1,791 | +46.92% |
Insider Historical Profitability
| Tempus AI, Inc. | 10 percent owner | 12718800 23.964% | $5.62 | 1 | 0 | |
| MYERS WOODROW A JR | director | 26116 0.0492% | $5.62 | 1 | 0 | |
| Lightspeed Venture Partners Select IV, L.P. | director | 1774240 3.3429% | $5.62 | 3 | 0 | +58.12% |
| LUDLUM KEN | director | 30000 0.0565% | $5.62 | 1 | 1 | <0.0001% |
| RICCI PAUL | director | 20000 0.0377% | $5.62 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| ARK Investment Management LLC | $9.04M | 11.68 | 6.07M | -9.08% | -$903,047.30 | 0.03 | |
| BlackRock | $4.89M | 6.32 | 3.28M | -1.04% | -$51,475.02 | <0.0001 | |
| The Vanguard Group | $2.84M | 3.67 | 1.9M | -8.02% | -$247,234.22 | <0.0001 | |
| Renaissance Technologies | $1.64M | 2.11 | 1.1M | +30.53% | +$382,414.85 | <0.01 | |
| Acadian Asset Management | $1.48M | 1.91 | 991,828 | +90.67% | +$701,885.30 | 0.01 |